Brokerages Set Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) Price Target at $60.40

Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) has earned an average rating of “Moderate Buy” from the thirteen analysts that are presently covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation, three have given a hold recommendation, eight have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price target among brokers that have issued a report on the stock in the last year is $60.40.

Several equities research analysts have recently issued reports on IMCR shares. Weiss Ratings reissued a “sell (e+)” rating on shares of Immunocore in a research report on Thursday, January 22nd. HC Wainwright reiterated a “buy” rating and issued a $100.00 price target on shares of Immunocore in a report on Wednesday, February 4th. Wells Fargo & Company began coverage on Immunocore in a research note on Friday, October 31st. They set an “overweight” rating and a $60.00 price objective on the stock. Zacks Research upgraded Immunocore from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, January 7th. Finally, Wall Street Zen lowered Immunocore from a “buy” rating to a “hold” rating in a research report on Saturday, January 31st.

Immunocore Stock Performance

NASDAQ IMCR opened at $32.28 on Monday. The company has a debt-to-equity ratio of 0.99, a current ratio of 6.00 and a quick ratio of 5.97. Immunocore has a 1-year low of $23.15 and a 1-year high of $40.71. The firm has a market capitalization of $1.63 billion, a P/E ratio of -56.63 and a beta of 0.78. The business’s 50-day simple moving average is $34.22 and its 200-day simple moving average is $34.32.

Institutional Investors Weigh In On Immunocore

Several hedge funds and other institutional investors have recently added to or reduced their stakes in IMCR. Bellevue Group AG lifted its holdings in Immunocore by 99.9% in the 2nd quarter. Bellevue Group AG now owns 2,441,830 shares of the company’s stock worth $76,625,000 after buying an additional 1,220,036 shares in the last quarter. Primecap Management Co. CA increased its position in shares of Immunocore by 40.8% during the second quarter. Primecap Management Co. CA now owns 3,771,474 shares of the company’s stock worth $118,349,000 after acquiring an additional 1,092,824 shares during the last quarter. BVF Inc. IL acquired a new position in shares of Immunocore in the second quarter worth about $32,142,000. Millennium Management LLC boosted its holdings in Immunocore by 334.3% in the third quarter. Millennium Management LLC now owns 1,265,965 shares of the company’s stock valued at $45,993,000 after purchasing an additional 974,463 shares during the last quarter. Finally, Fiera Capital Corp grew its stake in Immunocore by 31.4% during the 4th quarter. Fiera Capital Corp now owns 1,044,831 shares of the company’s stock valued at $36,266,000 after purchasing an additional 249,674 shares in the last quarter. Hedge funds and other institutional investors own 84.50% of the company’s stock.

About Immunocore

Immunocore plc is a clinical‐stage biotechnology company focused on the development of novel immunotherapies that harness the body’s own T‐cell response to treat cancer and infectious diseases. The company’s proprietary ImmTAC (immune mobilising monoclonal T‐cell receptors against cancer) platform utilizes engineered, soluble T‐cell receptor (TCR) molecules designed to recognise intracellular peptide–HLA complexes. By redirecting and activating T cells against disease‐associated targets, Immunocore aims to address malignancies and persistent viral infections with high unmet medical need.

The company’s most advanced candidate, tebentafusp, is a bispecific ImmTAC molecule that targets gp100, a melanoma‐associated antigen, and has received regulatory approval for the treatment of metastatic uveal melanoma.